Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free RDY Stock Alerts

Dr. Reddy's Laboratories (RDY) Competitors

Dr. Reddy's Laboratories logo
$12.46 +0.32 (+2.59%)
Closing price 03:59 PM Eastern
Extended Trading
$12.44 -0.02 (-0.16%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

RDY vs. TEVA, ONC, RPRX, ZTS, and VTRS

Should you buy Dr. Reddy's Laboratories stock or one of its competitors? Dr. Reddy's Laboratories's main competitors and comparable companies include Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Royalty Pharma (RPRX), Zoetis (ZTS), and Viatris (VTRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Dr. Reddy's Laboratories compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Teva Pharmaceutical Industries currently has a consensus price target of $42.00, suggesting a potential upside of 15.14%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, research analysts plainly believe Teva Pharmaceutical Industries is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
Dr. Reddy's Laboratories
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Dr. Reddy's Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries4.08% 32.64% 6.34%
Dr. Reddy's Laboratories 10.15%9.49%6.32%

In the previous week, Dr. Reddy's Laboratories had 1 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 14 mentions for Dr. Reddy's Laboratories and 13 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 1.09 beat Dr. Reddy's Laboratories' score of 0.93 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
10 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Dr. Reddy's Laboratories
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Teva Pharmaceutical Industries has higher revenue and earnings than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.26B2.46$1.41B$0.6060.79
Dr. Reddy's Laboratories$3.58B2.91$456M$0.4428.33

Teva Pharmaceutical Industries has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market.

Summary

Teva Pharmaceutical Industries beats Dr. Reddy's Laboratories on 12 of the 16 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to BeOne Medicines?

Dr. Reddy's Laboratories (NYSE:RDY) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

BeOne Medicines has a consensus price target of $402.14, suggesting a potential upside of 11.93%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dr. Reddy's Laboratories
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
BeOne Medicines
1 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
3 Strong Buy rating(s)
3.00

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 6.2% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has higher earnings, but lower revenue than BeOne Medicines. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$3.58B2.91$456M$0.4428.33
BeOne Medicines$5.34B7.38$286.93M$5.6863.25

BeOne Medicines has a net margin of 10.70% compared to Dr. Reddy's Laboratories' net margin of 10.15%. BeOne Medicines' return on equity of 14.23% beat Dr. Reddy's Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Dr. Reddy's Laboratories10.15% 9.49% 6.32%
BeOne Medicines 10.70%14.23%7.82%

In the previous week, BeOne Medicines had 21 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 35 mentions for BeOne Medicines and 14 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.93 beat BeOne Medicines' score of 0.48 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dr. Reddy's Laboratories
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BeOne Medicines
10 Very Positive mention(s)
3 Positive mention(s)
11 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Dr. Reddy's Laboratories has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market.

Summary

BeOne Medicines beats Dr. Reddy's Laboratories on 15 of the 17 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Dr. Reddy's Laboratories (NYSE:RDY) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

54.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Royalty Pharma has a net margin of 32.14% compared to Dr. Reddy's Laboratories' net margin of 10.15%. Royalty Pharma's return on equity of 30.01% beat Dr. Reddy's Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Royalty Pharma32.14% 30.01% 14.91%
Dr. Reddy's Laboratories 10.15%9.49%6.32%

In the previous week, Royalty Pharma had 4 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 18 mentions for Royalty Pharma and 14 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.93 beat Royalty Pharma's score of 0.90 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Royalty Pharma
6 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Dr. Reddy's Laboratories
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Royalty Pharma pays an annual dividend of $0.94 per share and has a dividend yield of 1.6%. Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Royalty Pharma pays out 64.8% of its earnings in the form of a dividend. Dr. Reddy's Laboratories pays out 13.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has increased its dividend for 5 consecutive years. Royalty Pharma is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Royalty Pharma has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Royalty Pharma currently has a consensus target price of $60.86, indicating a potential upside of 5.31%. Given Royalty Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Royalty Pharma is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Royalty Pharma
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00
Dr. Reddy's Laboratories
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

Royalty Pharma has higher earnings, but lower revenue than Dr. Reddy's Laboratories. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Royalty Pharma$2.38B13.99$770.95M$1.4539.86
Dr. Reddy's Laboratories$3.58B2.91$456M$0.4428.33

Summary

Royalty Pharma beats Dr. Reddy's Laboratories on 16 of the 19 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Zoetis?

Dr. Reddy's Laboratories (NYSE:RDY) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Dr. Reddy's Laboratories has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Zoetis has higher revenue and earnings than Dr. Reddy's Laboratories. Zoetis is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$3.58B2.91$456M$0.4428.33
Zoetis$9.47B3.28$2.67B$6.0712.39

In the previous week, Zoetis had 37 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 51 mentions for Zoetis and 14 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.93 beat Zoetis' score of 0.50 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dr. Reddy's Laboratories
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zoetis
14 Very Positive mention(s)
8 Positive mention(s)
12 Neutral mention(s)
7 Negative mention(s)
2 Very Negative mention(s)
Positive

Zoetis has a consensus price target of $109.62, suggesting a potential upside of 45.70%. Given Zoetis' stronger consensus rating and higher probable upside, analysts plainly believe Zoetis is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dr. Reddy's Laboratories
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Zoetis
1 Sell rating(s)
9 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.39

Zoetis has a net margin of 27.49% compared to Dr. Reddy's Laboratories' net margin of 10.15%. Zoetis' return on equity of 74.89% beat Dr. Reddy's Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Dr. Reddy's Laboratories10.15% 9.49% 6.32%
Zoetis 27.49%74.89%18.59%

Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Zoetis pays an annual dividend of $2.12 per share and has a dividend yield of 2.8%. Dr. Reddy's Laboratories pays out 13.6% of its earnings in the form of a dividend. Zoetis pays out 34.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 14 consecutive years. Zoetis is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Zoetis beats Dr. Reddy's Laboratories on 15 of the 19 factors compared between the two stocks.

How does Dr. Reddy's Laboratories compare to Viatris?

Dr. Reddy's Laboratories (NYSE:RDY) and Viatris (NASDAQ:VTRS) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Viatris has a consensus price target of $17.50, indicating a potential upside of 7.49%. Given Viatris' stronger consensus rating and higher probable upside, analysts clearly believe Viatris is more favorable than Dr. Reddy's Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dr. Reddy's Laboratories
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Viatris
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

Dr. Reddy's Laboratories has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dr. Reddy's Laboratories$3.58B2.91$456M$0.4428.33
Viatris$14.30B1.31-$3.51B-$0.36N/A

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Dr. Reddy's Laboratories had 4 more articles in the media than Viatris. MarketBeat recorded 14 mentions for Dr. Reddy's Laboratories and 10 mentions for Viatris. Dr. Reddy's Laboratories' average media sentiment score of 0.93 beat Viatris' score of 0.49 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dr. Reddy's Laboratories
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Viatris
0 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Dr. Reddy's Laboratories has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Viatris has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 2.9%. Dr. Reddy's Laboratories pays out 13.6% of its earnings in the form of a dividend. Viatris pays out -133.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Viatris is clearly the better dividend stock, given its higher yield and lower payout ratio.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Viatris' net margin of -2.79%. Viatris' return on equity of 20.02% beat Dr. Reddy's Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Dr. Reddy's Laboratories10.15% 9.49% 6.32%
Viatris -2.79%20.02%8.02%

Summary

Viatris beats Dr. Reddy's Laboratories on 10 of the 18 factors compared between the two stocks.

Get Dr. Reddy's Laboratories News Delivered to You Automatically

Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RDY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RDY vs. The Competition

Export
MetricDr. Reddy's LaboratoriesPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$10.14B$12.02B$7.09B$24.25B
Dividend Yield0.53%2.69%2.57%3.70%
P/E Ratio28.33783.52268.1530.30
Price / Sales2.91741.20584.9921.24
Price / Cash14.3470.0072.2633.15
Price / Book2.5410.5613.216.54
Net Income$456M$2.78B$3.44B$1.06B
7 Day Performance2.89%0.89%2.27%0.17%
1 Month Performance-5.68%-1.48%-0.23%2.41%
1 Year Performance-9.71%182.35%76.15%20.41%

Dr. Reddy's Laboratories Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RDY
Dr. Reddy's Laboratories
2.7663 of 5 stars		$12.47
+2.6%		N/A-12.1%$10.14B$3.58B28.3327,527
TEVA
Teva Pharmaceutical Industries
3.9744 of 5 stars		$34.69
-0.1%		$42.00
+21.1%		+120.6%$39.80B$17.26B57.6933,950
ONC
BeOne Medicines
4.2881 of 5 stars		$328.83
+0.4%		$395.77
+20.4%		+24.6%$36.15B$5.74B73.7112,000
RPRX
Royalty Pharma
4.5932 of 5 stars		$57.14
-1.1%		$56.57
-1.0%		+54.3%$32.84B$2.54B38.8080
ZTS
Zoetis
4.9638 of 5 stars		$75.86
+2.0%		$118.33
+56.0%		-49.4%$31.59B$9.53B12.5014,500

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:RDY) was last updated on 8/11/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel